WO2014143941A1 - Stabilized modified release vitamin d formulation and method of administring same - Google Patents

Stabilized modified release vitamin d formulation and method of administring same Download PDF

Info

Publication number
WO2014143941A1
WO2014143941A1 PCT/US2014/028132 US2014028132W WO2014143941A1 WO 2014143941 A1 WO2014143941 A1 WO 2014143941A1 US 2014028132 W US2014028132 W US 2014028132W WO 2014143941 A1 WO2014143941 A1 WO 2014143941A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
hours
dosage form
hydroxyvitamin
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/028132
Other languages
English (en)
French (fr)
Inventor
Jay A. White
Joel Z. Melnick
Sammy A. Agudoawu
Samir P. Tabash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko IP Holdings II Inc
Original Assignee
Opko IP Holdings II Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50478969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014143941(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP21157479.3A priority Critical patent/EP3888638A1/en
Priority to HK16108396.5A priority patent/HK1220362B/en
Priority to UAA201510090A priority patent/UA123386C2/uk
Priority to CA2905409A priority patent/CA2905409C/en
Priority to DK14717038.5T priority patent/DK2968172T3/da
Priority to HK16108226.1A priority patent/HK1220128A1/zh
Priority to SM20200424T priority patent/SMT202000424T1/it
Priority to EA201591809A priority patent/EA038867B1/ru
Priority to PL19217651T priority patent/PL3650016T3/pl
Priority to PL14717038T priority patent/PL2968172T3/pl
Priority to EP19217651.9A priority patent/EP3650016B1/en
Priority to BR112015023658A priority patent/BR112015023658A2/pt
Priority to SI201431628T priority patent/SI2968172T1/sl
Priority to NZ711924A priority patent/NZ711924B2/en
Priority to AU2014228069A priority patent/AU2014228069B2/en
Priority to PL18155036T priority patent/PL3332773T3/pl
Priority to JP2016502712A priority patent/JP6492051B2/ja
Application filed by Opko IP Holdings II Inc filed Critical Opko IP Holdings II Inc
Priority to CN201480024061.XA priority patent/CN105246464A/zh
Priority to ES14717038T priority patent/ES2809477T3/es
Priority to MYPI2015002281A priority patent/MY194092A/en
Priority to HRP20201284TT priority patent/HRP20201284T1/hr
Priority to CN202010255439.4A priority patent/CN111346071B/zh
Priority to RS20200963A priority patent/RS60846B1/sr
Priority to MX2015012625A priority patent/MX2015012625A/es
Priority to EP14717038.5A priority patent/EP2968172B8/en
Priority to SG11201507323PA priority patent/SG11201507323PA/en
Priority to EP18155036.9A priority patent/EP3332773B8/en
Priority to CR20190178A priority patent/CR20190178A/es
Priority to LTEP14717038.5T priority patent/LT2968172T/lt
Publication of WO2014143941A1 publication Critical patent/WO2014143941A1/en
Priority to IL241456A priority patent/IL241456B/en
Anticipated expiration legal-status Critical
Priority to SA515361134A priority patent/SA515361134B1/ar
Priority to PH12015502162A priority patent/PH12015502162A1/en
Priority to AU2019200268A priority patent/AU2019200268B2/en
Priority to IL274841A priority patent/IL274841A/en
Priority to CY20201100727T priority patent/CY1123167T1/el
Priority to CY20201101109T priority patent/CY1123568T1/el
Priority to NO2021007C priority patent/NO2021007I1/no
Priority to PH12021551127A priority patent/PH12021551127A1/en
Priority to CY20211100683T priority patent/CY1124393T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the disclosure relates generally to controlled release pharmaceutical compositions. More particularly, the invention relates to controlled-release formulations for delivery of a vitamin D compound for intestinal absorption, such as a 25-hydroxyvitamin D compound, which are shelf-stable over time.
  • a vitamin D compound for intestinal absorption such as a 25-hydroxyvitamin D compound
  • the Vitamin D metabolites known as 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are fat-soluble steroid prohormones that contribute to the maintenance of normal levels of calcium and phosphorus in the bloodstream.
  • the prohormone 25-hydroxyvitamin D 2 is produced from Vitamin D 2 (ergocalciferol)
  • 25- hydroxyvitamin D 3 is produced from Vitamin D 3 (cholecalciferol), primarily by one or more enzymes located in the liver.
  • the two prohormones also can be produced outside of the liver from Vitamin D 2 and Vitamin D 3 (collectively referred to as "Vitamin D") in certain cells, such as enterocytes, which contain enzymes identical or similar to those found in the liver.
  • the 25-hydroxyvitamin D prohormones are further metabolized in the kidneys into potent Vitamin D hormones.
  • the prohormone 25-hydroxyvitamin D 2 is metabolized into l ,25- dihydroxyvitamin D 2 ; likewise, 25-hydroxyvitamin D 3 is metabolized into l ,25- dihydroxyvitamin D 3 (calcitriol).
  • Production of these active hormones from the 25- hydroxyvitamin D prohormones also can occur outside of the kidney in cells which contain the required enzyme(s).
  • Controlled release formulations of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 can be administered to treat 25-hydroxyvitamin D insufficiency and deficiency without supraphysio logical surges in intraluminal, intracellular and blood levels of 25-hydroxyvitamin D and their consequences; without causing substantially increased catabolism of the administered 25-hydroxyvitamin D; and, without causing serious side effects associated with Vitamin D supplementation, namely Vitamin D toxicity.
  • the controlled release formulations effectively lower PTH levels without undesirable increases in serum calcium and serum phosphorus and are therefore useful for treating secondary hyperparathyroidism, for example in CKD patients. See International Patent Application Nos. PCT/US2007/061521 and PCT/US2008/061579 and U.S. Patent Application No. 12/109,983, incorporated herein by reference.
  • the controlled released compositions provide substantially increased absorption of 25- hydroxyvitamin D via transport on DBP and decreased absorption via transport in chylomicrons.
  • the compositions also provide maintenance of substantially constant blood levels of 25- hydroxyvitamin D during a 24-hour post-dosing period.
  • circulating DBP renal plasma protein
  • intraluminal and intracellular 25- hydroxyvitamin D concentration spikes i.e., supraphysio logic levels and related unwanted catabolism can be mitigated or eliminated.
  • serum levels of 25-hydroxyvitamin D can be increased and maintained more predictably than by administration of immediate release formulations, allowing for a consistent dosage and reducing or eliminating the need for frequent patient monitoring.
  • the present invention comprises a controlled release Vitamin D formulation comprising a vitamin D compound and a cellulosic compound.
  • the present invention also comprises a storage-stabilized formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation.
  • the stabilized formulation comprises one or both of 25- hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 and a stabilizing agent or stabilizing compound, e.g. a cellulosic compound.
  • the stabilized formulations of the invention with the recited stabilizing agent(s) can have improved or relatively improved "storage stability", or stability following aging, as well as one or more additional characteristics including improved physical, chemical and biological properties when compared to the disclosed formulations that do not contain such agents.
  • the claimed formulations are thus suitable as therapeutics that possess a long shelf life as well as improved bioavailability compared to aged, unstable formulations.
  • the stabilized formulation includes one or both of 25- hydroxyvitamin D 2 and 25-hydroxyvitamin D3, a lipophilic matrix (e.g. a wax matrix), and a stabilizing agent (e.g., a cellulosic compound).
  • a stabilized formulation includes one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D3, a wax matrix, and a cellulosic stabilizing agent.
  • the formulation includes one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D3, a wax matrix, and an effective amount of a cellulosic compound to maintain an advantageous degree of stabilization described herein.
  • the stabilized formulation comprises a mixture of an active-loaded wax matrix comprising one or both of 25-hydroxyvitamin D 2 and 25- hydroxyvitamin D3 and a cellulosic stabilizing agent, wherein the formulation releases an amount of 25-hydroxyvitamin D during in vitro dissolution after exposure to storage conditions of at least one month at 25 °C and 60% relative humidity that varies at all dissolution testing time points by 30% or less compared to the amount released at the same dissolution time points during in vitro dissolution conducted on fresh product.
  • the formulation is an improvement formulation for controlled release of a vitamin D compound.
  • the improvement comprises admixing a stabilizing agent into a formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation.
  • the improvement comprises an effective amount of a cellulosic compound admixed into a formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation to provide an advantageous degree of stability described herein.
  • Figure 1 shows the dissolution profile of formulations according to the disclosure after storage for 0 to 24 months at 25 °C and 60% relative humidity. The dissolution time in hours is depicted on the x-axis and the mean percent of 25-hydroxyvitamin D 3 dissolved is shown on the y-axis.
  • Figures 1A, IB, and 1C show the dissolution profile of formulations comprising 30 ⁇ g, 60 ⁇ g, and 90 ⁇ g of 25-hydroxyvitamin D 3 , respectively.
  • Figure 2 shows the dissolution profile of formulations according to the disclosure after storage for 0 to 6 months at 40 °C and 75% relative humidity. The dissolution time in hours is depicted on the x-axis and the mean percent of 25-hydroxyvitamin D 3 dissolved is shown on the y-axis.
  • Figures 2A, 2B, and 2C show the dissolution profile of formulations comprising 30 ⁇ g, 60 ⁇ g, and 90 ⁇ g of 25-hydroxyvitamin D 3 , respectively.
  • Figure 3 shows the dissolution profile of formulations after storage for 0 to 12 months at 25 °C and 60% relative humidity. The dissolution time in hours is depicted on the x-axis and the mean % Label Claim of 25-hydroxyvitamin D 3 released is shown on the y-axis.
  • Figure 3A shows the dissolution profile of a comparative formulation that does not contain a cellulosic compound.
  • Figure 3B shows the dissolution profile of a stabilized formulation according to the disclosure.
  • Figure 4 shows the resulting mean baseline-adjusted calcifediol concentrations by treatment group (PK population) for the patients described in Example 4 treated with a formulation according to the disclosure.
  • Figure 5 shows the resulting summary baseline-adjusted PK parameters for calcifediol concentrations by treatment group (PK population) for the patients described in Example 4 treated with a formulation according to the disclosure.
  • Figure 6 shows the resulting mean baseline-adjusted serum 1,25-dihydroxyvitamin D levels during the 6-week treatment (PK population) for the patients described in Example 4 treated with a formulation according to the disclosure.
  • Figure 7 shows a summary of the resulting baseline-adjusted repeat-dose PK parameters for serum 1,25-dihydroxyvitamin D by treatment group (PK population) for the patients described in Example 4 treated with a formulation according to the disclosure.
  • Figure 8 shows the resulting mean percent of baseline in plasma iPTH levels during the 6-week treatment (PK population) for the patients described in Example 4 treated with a formulation according to the disclosure.
  • Figure 9 shows a summary of the resulting baseline-adjusted repeat-dose PK parameters for plasma iPTH by treatment group (PK population) for the patients described in Example 4 treated with a formulation according to the disclosure.
  • Figures 10 and 11 show the percent change from baseline at EOT for plasma iPTH relative to baseline-adjusted calcifediol and 1,25-dihydroxyvitamin D exposure (AUCo-6wk) in the PK Population for the patients described in Example 4 treated with a formulation according to the disclosure.
  • controlled release and “modified release” are used interchangeably and refer to the release of the administered vitamin D compound in a way that deviates from immediate release.
  • sustained release and “extended release” are used interchangeably and refer to the release of the administered vitamin D compound over a longer period of time than a comparable immediate release formulation, resulting in serum concentrations of the vitamin D compound that remain elevated over baseline for a longer period of time than for a comparable immediate release formulation.
  • the foregoing terms optionally include delayed release characteristics.
  • a delayed release type of controlled release formulation will be characterized by Cmax at a time greater than Cmax for an immediate release formulation.
  • the release of a 25-hydroxyvitamin D compound will preferably be at such a rate that total serum or blood levels of 25-hydroxyvitamin D are maintained or elevated above predosing levels for an extended period of time, e.g. 4 to 24 hours or even longer.
  • the term "cellulosic compound” can include cellulose (C 6 Hio0 5 ) n or a derivative of cellulose, unless specified otherwise.
  • a "cellulose ether” is a cellulose derivative that has been chemically modified to result in partial or complete etherification of the hydroxyl groups in the cellulose molecule.
  • Examples of cellulose derivatives which can be used as stabilizing agents include, but are not limited to, celluloronic acid, carboxy methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyl propyl cellulose, hydroxyl propyl
  • methylcellulose methylcellulose, methyl cellulose, polyanionic cellulose, and combinations thereof, for example.
  • Different grades of each cellulosic compound or stabilizing agent corresponding to variations in, e.g., molecular weight, viscosity, solubility, and hydration, are also encompassed by the terms.
  • vitamin D compound suitable for prophylactic and/or therapeutic use are contemplated for inclusion in the formulation described herein.
  • Vitamin D 25-hydroxyvitamin D 1,25-dihydroxyvitamin D, and other metabolites and analogs of Vitamin D are also useful as active compounds in pharmaceutical compositions. Specific examples include, but are not limited to, Vitamin D 3 (cholecalciferol), Vitamin D 2
  • the vitamin D compound includes one or more hydroxy forms, such as a combination of 25-hydroxyvitamin D 3 and 25-hydroxyvitamin D 2 .
  • a type of vitamin D compound particularly contemplated for use in the formulation disclosed herein can include 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination thereof.
  • 25-hydroxyvitamin D 3 is particularly contemplated.
  • the term 25- hydroxyvitamin D refers to one or more of 25-hydroxyvitamin D 3 , 25-hydroxyvitamin D 2 , 25- hydroxyvitamin D 4 , 25-hydroxyvitamin D5, or 25-hydroxyvitamin D 7 , and it is contemplated that in any reference thereto a preferred embodiment is one or more of 25-hydroxyvitamin D 3 and 25- hydroxyvitamin D 2 , preferably 25-hydroxyvitamin D 3 .
  • the active can include one or both of 25- hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , particularly 25-hydroxyvitamin D 3 .
  • the vitamin D compound (or combination thereof) is also referred to as the "active" part of the formulation (or “active” agents), as distinguished from the controlled release matrix, the stabilizing agent, and other excipients.
  • references to 25-hydroxyvitamin D should be interpreted to mean 25-hydroxyvitamin D 3
  • all pharmacokinetic (PK) results associated with e.g., t max , C max , AUC
  • PK pharmacokinetic
  • a "stabilized" formulation refers to a formulation exhibiting a stable in vitro dissolution profile (according to any of the parameters described further herein) and controlled release (e.g., sustained release) of a vitamin D compound in vivo, for a time following initial manufacture, e.g. following actual shelf storage or accelerated stability storage conditions.
  • the release of the active ingredient can be measured using a suitable in vitro dissolution method, such as one of the methods already known in the art.
  • the in vitro dissolution method is United States Pharmacopeia, USP 29-NF 24, Dissolution ⁇ 711> physical tests and determinations, United States Pharmacopeial Convention, Inc., Rockville, MD, 2006, pp. 2673-2682, using Apparatus 2 (paddle method), as described in the Examples below.
  • t max (or Tmax) is defined as the time for the plasma concentration of the active compound to reach its maximum in a dose interval following administration of a formulation according to the invention.
  • tmax is defined as the time for the plasma concentration of serum 25-hydroxyvitamin D 3 to reach its maximum in a dose interval following administration of the formulation, unless specified otherwise.
  • Vitamin D sufficiency is defined as serum 25-hydroxyvitamin D levels > 30 ng/mL
  • Vitamin D insufficiency is defined as serum 25-hydroxyvitamin D of 16-30 ng/mL
  • mild Vitamin D deficiency is defined as serum 25- hydroxyvitamin D of 5-15 ng/mL
  • severe Vitamin D deficiency is defined as serum 25- hydroxyvitamin D below 5 ng/mL.
  • any numerical value recited herein includes all values from the lower value to the upper value, i.e., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application.
  • a concentration range or a beneficial effect range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification.
  • a stated concentration of about 20% is intended to include values from 19.5% up to 20.5%>.
  • compositions for controlled release of a Vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation.
  • the formulation will include a vitamin D compound as described herein, a matrix component that releasably binds the vitamin D compound and controllably releases the vitamin D compound (e.g., a lipophilic matrix), and a stabilizer (e.g. a cellulosic compound).
  • a stabilized formulation according to the disclosure herein following storage for a period of time, releases an amount of 25-hydroxyvitamin D in in vitro dissolution that does not substantially differ from the dissolution of the same formulation just after manufacturing and prior to storage.
  • a formulation releases an amount of 25- hydroxyvitamin D during in vitro dissolution after exposure to storage conditions of two months at 25 °C and 60% relative humidity that varies at any given dissolution time point after four hours by 30%> or less compared to the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions (i.e., freshly-produced product).
  • the table below provides examples of advantageous degrees of storage stability contemplated for embodiments of the invention following storage at 25 °C and 60% RH, and alternatively at 40°C and 75% RH for various times following initial manufacturing, and at various times in during dissolution testing.
  • the degrees of storage stability are expressed in terms of the maximum deviation from nominal active potency, i.e. maximum % change from LC. Alternative embodiments of maximum deviation are also provided.
  • the formulation will have advantageous degrees of stability described in the table immediately above at multiple time points throughout the dissolution testing, e.g. at least at both 2 and 4 hour time points, optionally also at the 6 hour time point, further optionally also at the 8 hour time point, and further optionally also at the 12 hour time point, such that the dissolution profile after storage follows the dissolution profile of fresh product.
  • the formulation will have advantageous degrees of stability described in the table immediately above at least at the 2, 6, and 12 hour time points.
  • the formulation will have advantageous degrees of stability described in the table immediately above at least at the 4, 8, and 12 hour time points.
  • the formulation will have
  • the formulation will have advantageous degrees of stability described in the table immediately above at least at the 4, 6, 8, and 12 hour time points, or at all times of 4 hours and thereafter.
  • the deviation can be positive (more release) or negative (less release) with respect to the fresh product.
  • the deviation will be in the negative (less release) direction at multiple time points.
  • the deviation in dissolution release would have been negative (less release) at multiple time points but for the presence of the stabilizing agent in the formulation.
  • the dissolution release profile of the formulation can have the characteristics of any one of the examples provided herein below.
  • the formulation can be characterized by a dissolution release profile providing a release of vitamin D compound of less than 30% at 2 hours, greater than 45% at 6 hours, and greater than 80% at 12 hours, and further optionally less than 60% at 6 hours.
  • the formulation can be characterized by an in vitro dissolution profile providing release of vitamin D compound of less than 30% at 100 to 140 minutes, greater than 45% at 5 to 7 hours, and greater than 80% at 11 to 13 hours.
  • the formulation can be characterized by an in vitro dissolution profile providing release of vitamin D compound of less than 30% at 2 hours, greater than 45% at 6 hours, and greater than 80% at 12 hours.
  • optionally the release of vitamin D compound at 5 to 7 hours is less than 60%>, or at 6 hours is less than 60%>.
  • the formulation can be characterized by an in vitro dissolution profile providing release of vitamin D compound of about 20% to about 40% at 2 hours, at least 35% at 6 hours, and at least 70% at 12 hours.
  • the formulation can be characterized by an in vitro dissolution profile providing release of vitamin D compound of about 25% to about 35% at 2 hours, at least 40% at 6 hours, and at least 75% at 12 hours.
  • optionally the release of vitamin D compound is 75% or less at 6 hours, or 65%> or less at 6 hours, or 60%> or less at 6 hours, for example.
  • the stabilized formulation can be characterized by a t max following administration of the dosage form to a human patient, of at least 4 hours, or at least 8 hours, or at least 12 hours, or at least 18 hours, or at least 20 hours, or at least 24 hours, or at least 28 hours, for example in a range of 4 to 96 hours, or in a range of 18 to 30 hours, or in a range of 13 to 28 hours, or is 28 hours, for example.
  • a formulation comprising 25- hydroxyvitamin D can be characterized by providing a baseline-adjusted C max per microgram of 25-hydroxyvitamin D in a range of about 0.0133 ng/mL to about 0.04 ng/mL when administered to an adult human.
  • the method can include administering a stabilized sustained release dosage form comprising a 25-hydroxyvitamin D compound to a human patient, comprising administering an effective amount of the formulation to the patient to provide a baseline-adjusted C max of at least about 0.2 ng/mL and optionally less than 1 10 ng/mL, and further optionally 24 ng/mL or less, for example in a range of about 0.2 to about 24 ng/mL.
  • the method can include administering a stabilized sustained release dosage form comprising a 25-hydroxyvitamin D compound to a human patient, comprising administering an effective amount of the formulation to the patient to provide a baseline-adjusted AUCo-inf of at least 52 ng*h/mL, and optionally less than 34,500 ng*h/mL, and further optionally about 12,000 ng*h/mL or less, for example in a range of about 52 ng*h/mL to about 12,000 ng*h/mL.
  • the stabilized formulation, following storage can be bioequivalent to the freshly-made product.
  • the stabilized formulation, following storage can provide an area under the curve for the active (or serum total 25-hydroxyvitamin D), AUC (e.g., AUCo-inf or AUC 0-t ) within a 90% confidence interval, or within 80% to 125% of the mean, or within 80% to 120% of the mean of the fresh product.
  • AUC e.g., AUCo-inf or AUC 0-t
  • the stabilized formulation following storage, can provide a maximum serum concentration of the active (or serum total 25-hydroxyvitamin D), Cmax (e.g., C max absolute, or Cmax compared to baseline) within a 90%> confidence interval, or within 80% to 125% of the mean, or within 80% to 120% of the mean, of the fresh product.
  • Cmax e.g., C max absolute, or Cmax compared to baseline
  • a stabilized formulation comprises one or both of 25- hydroxyvitamin D 2 and 25-hydroxyvitamin D3, a wax matrix, and a cellulosic compound.
  • a stabilized formulation comprises one or both of 25-hydroxyvitamin D 2 and 25- hydroxyvitamin D3, a wax matrix, and a cellulosic stabilizing agent.
  • the formulation comprises one or both of 25-hydroxyvitamin D 2 and 25 -hydro xyvitamin D 3 , a wax matrix, and an effective amount of a cellulosic compound to provide an advantageous degree of stability as described herein, e.g. with respect to the table immediately above or consistent with any of the Examples described below.
  • the amount can be effective to provide a difference of 30% or less between the amount of active released during in vitro dissolution after exposure to storage conditions of at least one month at 25 °C and 60% relative humidity at a dissolution time point and the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions, while a comparative formulation lacking the stabilizing agent would result in a greater difference in dissolution release following the same storage conditions.
  • the formulation is an improved formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation.
  • the improvement comprises admixing a cellulosic stabilizing agent into a formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation.
  • the improvement comprises an effective amount of a cellulosic compound admixed into a formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation to provide an advantageous degree of stability as described herein, e.g. with respect to the table immediately above or consistent with any of the Examples described below.
  • the amount can be effective to provide a difference of 30% or less between the amount of active released during in vitro dissolution after exposure to storage conditions of at least one month at 25 °C and 60% relative humidity at a dissolution time point and the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions, while a comparative formulation lacking the stabilizing agent would result in a greater difference in dissolution release following the same storage conditions.
  • the stabilizing agents can include cellulose compounds.
  • cellulose compounds and stabilizing agents for use in the stabilized formulations of the disclosure can include, but are not limited to, celluloronic acid, carboxy methyl cellulose, ethyl cellulose, hydroxyl ethyl cellulose, hydroxyl propyl cellulose, hydroxyl propyl methyl cellulose, methylcellulose, polyanionic cellulose, and combinations thereof.
  • poloxamers e.g., polaxamer 407
  • poly (ethylene oxide) polymers e.g., Dow's POLYOX polymers
  • povidones e.g., povidones
  • fumed silicas e.g., AEROSIL 200, Evonik Industries AG, Essen, Germany.
  • the stabilizer e.g. a cellulosic compound, preferably is present in an amount of at least about 5 % of the formulation, based on the total weight of the formulation excluding any additional coatings or shells (wt%).
  • the cellulosic compound can be present in an amount of at least 5 wt% of the formulation, or at least 10 wt% of the formulation, or at least 15 wt% of the formulation, or greater than 5 wt% of the formulation, or greater than 10 wt% of the formulation, or greater than 15 wt% of the formulation.
  • Suitable ranges include 5 wt% to 30 wt%, 10 wt% to 20 wt%, 10 wt% to 15 wt%, 5 wt% to 15 wt%, and 7.5 wt% to 12.5 wt.%.
  • the stabilizing agent referred to herein is an agent that stabilizes the dissolution release profile (and thus also the in vivo release profile) against substantial change over time during storage conditions, e.g. typical shelf storage conditions.
  • Other agents which are known in the art as preservatives for preventing degradation of the active component itself are not intended to be encompassed within the terms "stabilizing agent” and "stabilizer” although such
  • preservatives are also contemplated for use in the formulations of the present invention.
  • the cellulosic compound is a cellulose ether.
  • cellulose ethers include, but are not limited to, methylcellulose, hydroxyl propyl methylcellulose, hydroxyl ethyl methylcellulose, hydroxyl ethyl cellulose, hydroxyl propyl cellulose, and combinations thereof.
  • HPMC Hydroxyl propyl methylcellulose
  • the % methyoxyl component in the HPMC can be in a range of 19 to 24.
  • the % hydroxypropyl component can be in a range of 7 to 12.
  • the apparent viscosity (2% solution in water at 20°C) can be at least 50,000 cP, or at least 80,000 cP, or in a range of about 80 to 120,000 cP, or 3000 to 120,000 cP, or 11,000 to 120,000 cP, or
  • the apparent viscosity (2% solution in water at 20°C) can be in a range of 80,000 to 120,000 cP.
  • the pH (1% solution in water) can be in a range of 5.5 to
  • a suitable hydroxyl propyl methylcellulose having all of the foregoing properties, including an apparent viscosity (2% solution in water at 20°C) in a range of 80,000 to
  • the cellulosic compound will be insoluble in the matrix formulation at the melt point of the primary components of the matrix, e.g., at 65 °C or in a range of 60 °C to 75 °C.
  • the cellulosic compound will be hydrophilic.
  • a stabilized formulation according to the disclosure comprises a mixture of an active-loaded lipophilic matrix comprising one or both of 25-hydroxyvitamin D 2 and 25- hydroxyvitamin D 3 and a cellulosic stabilizing agent, wherein the formulation releases an amount of 25-hydroxyvitamin D during in vitro dissolution after exposure to storage conditions of at least one month at 25 °C and 60% relative humidity that varies at any given dissolution time point by 30% or less compared to the amount released at the same dissolution time point during in vitro dissolution conducted on freshly-made product.
  • Formulations that are not stabilized exhibit changes in the amount of active ingredient released after the composition is stored for a period of time, as shown in the Examples below.
  • An unstabilized formulation releases an amount of 25-hydroxyvitamin D following exposure to storage conditions that can vary at a given dissolution time point, for example by more than 30% compared to the amount released at the same dissolution time point during in vitro dissolution conducted on freshly-made product.
  • the changes may be an increase or decrease in the dissolution rate at a given time point, and such changes produce a dissolution profile whose curve is distinct from the shape of the initial dissolution profile.
  • An unstabilized formulation also exhibits different in vivo effects compared to a stabilized formulation according to the disclosure, following storage as described herein, e.g.
  • a stabilized formulation demonstrates different clinical pharmacokinetic parameters, such as improved bioavailability, compared to an unstabilized formulation, following storage as described herein, e.g. following 3 months or more of storage at 25 °C and 60% RH.
  • a stabilized formulation according to the disclosure can have a base formulation which is storage unstable, combined with a stabilizing agent which renders the formulation storage stable as described herein.
  • the matrix that releasably binds and controllably releases the active component can be, for example, a lipophilic matrix, including a wax matrix.
  • a wax matrix can provide a formulation which is solid or semi-solid at room temperature and solid, semi-solid, or liquid at body temperature, preferably semi-solid or liquid at body temperature.
  • the wax matrix comprises a controlled release agent, an emulsifier, and an absorption enhancer.
  • controlled release agents suitable for use include, but are not limited to, waxes, including synthetic waxes, microcrystalline wax, paraffin wax, carnauba wax, and beeswax; polyethoxylated castor oil derivatives, hydrogenated vegetable oils, glyceryl mono-, di- or tribehenates; long-chain alcohols, such as stearyl alcohol, cetyl alcohol, and polyethylene glycol; and mixtures of any of the foregoing.
  • Non-digestible waxy substances such as hard paraffin wax, are preferred.
  • the controlled release agent can be present in an amount of at least 5 wt% of the formulation, or greater than about 5 wt% of the formulation.
  • the controlled release agent can comprise at least 5 wt% of the formulation or at least 10 wt% of the formulation, or at least 15 wt% of the formulation, or at least 20 wt% of the formulation, or at least 25 wt% of the formulation, or greater than 5 wt% of the formulation, or greater than 10 wt% of the formulation, or greater than 15 wt% of the formulation, or greater than 20 wt% of the formulation, and or greater than 25 wt% of the formulation.
  • the controlled release agent can be present in an amount 50 wt% or less, 40 wt% or less, 35 wt% or less, or 30 wt% or less. Suitable ranges include 5 wt% to 40 wt%, 10 wt% to 30 wt% and 15 wt% to 25 wt%. Examples include about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, about 20 wt%, about 21 wt%, about 22 wt%, about 23 wt%, about 24 wt%, and about 25 wt%.
  • emulsifiers suitable for use in the formulation include, but are not limited to, lipophilic agents having an HLB of less than 7, such as mixed fatty acid monoglycerides; mixed fatty acid diglycerides; mixtures of fatty acid mono- and diglycerides; lipophilic polyglycerol esters; glycerol esters including glyceryl monooleate, glyceryl dioleate, glyceryl monostearate, glyceryl distearate, glyceryl monopalmitate, and glyceryl dipalmitate; glyceryl- lacto esters of fatty acids; propylene glycol esters including propylene glycol monopalmitate, propylene glycol monostearate, and propylene glycol monooleate; sorbitan esters including sorbitan monostearate, sorbitan sesquioleate; fatty acids and their soaps including stearic acid, palmitic acid, and o
  • a preferred lipoidic agent is selected from glycerides and derivatives thereof.
  • Preferred glycerides are selected from the group consisting of medium or long chain glycerides, caprylocaproyl macrogolglycerides, and mixtures thereof.
  • Preferred medium chain glycerides include, but are not limited to, medium chain monoglycerides, medium chain diglycerides, caprylic/capric triglyceride, glyceryl monolaurate, glyceryl monostearate, caprylic/capric glycerides, glycerylmonocaprylate, glyceryl
  • caprylic/capric linoleic triglyceride monodicaprylate, caprylic/capric linoleic triglyceride, and caprylic/capric/succinic triglyceride.
  • Monoglycerides having a low melting point are preferred for making the formulation.
  • Preferred monoglycerides include but are not limited to, glyceryl monostearate, glyceryl monopalmitate, glyceryl monooleate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monolaurate, etc., preferably glycerol monostearate (GMS).
  • GMS is a natural emulsifying agent. It is oil soluble, but poorly soluble in water. GMS has an HLB value of 3.8.
  • the lipophilic emulsifier can be present in an amount in a range of about 10 wt% to about 40 wt%, or about 20 wt% to about 25 wt%, for example. Other examples include about 20 wt%, about 21 wt%, about 22 wt%, about 23 wt%, about 24 wt%, and about 25 wt%.
  • Suitable absorption enhancers include, but are not limited to,
  • caprylocaproyl macrogolglycerides such as polyethylene glycosylated glycerides, also known as polyglycolized glycerides or PEGylated glycerides.
  • PEGylated glycerides which may be employed in the composition include, but are not limited to, mixtures of monoglycerides, diglycerides, and triglycerides and monoesters and diesters of polyethylene glycol, polyethylene glycosylated almond glycerides, polyethylene glycosylated corn glycerides, and polyethylene glycosylated caprylic/capric triglyceride.
  • the absorption enhancer can have an HLB value from 13 to 18, or from 13 to 15.
  • GELUCIRE Global Engineering Chemical Company, Paramus, New Jersey, USA.
  • GELUCIRE is a well known excipient which is a family of fatty acid esters of glycerol and PEG esters, also known as polyglycolized glycerides.
  • GELUCIRE is used in various applications including preparing sustained release pharmaceutical compositions.
  • GELUCIRE compounds are inert, semi-solid waxy materials which are amphiphilic and are available with varying physical characteristics such as melting point, HLB, and solubilities in various solvents. They are surface active in nature and disperse or solubilize in aqueous media forming micelles, microscopic globules or vesicles.
  • GELUCIRE 44/14 a mixture of lauroyl macrogolglycerides and lauroyl polyoxylglycerides that has a melting point of 44 °C and a HLB of 14.
  • the absorption enhancer can be present in an amount of about 5 wt% to about 20 wt%, or about 8 wt% to about 15 wt%, for example. Other examples include about 8 wt%, about 9 wt%, about 10 wt%, about 11, wt% about 12 wt%, about 13 wt%, about 14 wt%, and about 15 wt%.
  • the low melting points of the wax matrix provide a means of incorporating the pharmaceutically active ingredients, e.g. the vitamin D compound such as 25-D 2 , 25-D 3 , or both, at temperatures from about 0 °C to about 50 °C above the melting point of the wax matrix and then filling the melt (solution and/or dispersion) in suitable capsules.
  • the capsules can be of any variety that is compatible with the temperature of the melt fill, including soft or hard gelatin capsules, and animal or vegetable gelatin capsules. The melt solidifies inside the capsules upon cooling to room temperature.
  • a stabilized formulation may further comprise an oily vehicle for the 25- hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 .
  • oily vehicle for the 25- hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 .
  • Any pharmaceutically-acceptable oil can be used. Examples include animal (e.g., fish), vegetable (e.g., soybean), and mineral oils. The oil preferably will readily dissolve the 25-hydroxyvitamin D compound used.
  • Preferred oily vehicles include non-digestible oils, such as mineral oils, particularly liquid paraffins, and squalene.
  • the oily vehicle can be present at a concentration in a range about 10 wt% to about 50 wt% of the formulation, or about 15 wt% to about 45 wt%, or about 20 wt% to about 40 wt%, or about 30 wt% to about 40 wt%, for example.
  • a suitable liquid paraffin can be characterized by one or more of the following parameters: specific gravity about 0.88 to 0.89; kinematic viscosity (40 °C) about 64 cSt to about 70 cSt; molecular weight 424; % paraffmic hydrocarbons about 59; and pour point -24 °C.
  • the ratio between the wax matrix and the oily vehicle can be optimized in order to achieve the desired rate of release of the vitamin D compound.
  • a heavier oil component is used, relatively less of the wax matrix can be used, and if a lighter oil component is used, then relatively more wax matrix can be used.
  • the stabilized controlled release compositions in accordance with the invention preferably are designed to contain concentrations of 25-hydroxyvitamin D 2 and/or 25- hydroxyvitamin D 3 of 1 to 1000 ⁇ g per unit dose, for example, and are prepared in such a manner as to effect controlled or substantially constant release of the 25-hydroxyvitamin D 2 /25- hydroxyvitamin D 3 , optionally into the ileum of the gastrointestinal tract, of humans or animals over an extended period of time.
  • Example dosages include 1 ⁇ g to 1000 ⁇ g per unit dose, 1 ⁇ g to 600 ⁇ g, 1 ⁇ g to 400 ⁇ g, 1 ⁇ g to 200 ⁇ g, 1 ⁇ g to 100 ⁇ g, 5 ⁇ g to 90 ⁇ g, 30 ⁇ g to 80 ⁇ g, 20 ⁇ g to 60 ⁇ g, 30 ⁇ g to 60 ⁇ g, 35 ⁇ g to 50 ⁇ g, 5 ⁇ g to 50 ⁇ g, and 10 ⁇ g to 25 ⁇ g, for example 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 40 ⁇ g, 50 ⁇ g, 60 ⁇ g, 70 ⁇ g, 80 ⁇ g, 90 ⁇ g, and 100 ⁇ g.
  • the controlled release formulation releases at least 70%, more preferably at least 80% of the vitamin D compound within the first 24 hours after dosing.
  • 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 or combinations thereof together with other therapeutic agents can be administered, e.g. orally, in accordance with the above described embodiments in dosage amounts of from 1 to 100 ⁇ g per day, for example.
  • the dose will be selected to provide an average rise in serum 25-hydroxyvitamin D 3 of about 1 to 3 ng/ml in a dose interval.
  • the formulations described herein can be administered to raise and preferably also maintain blood 1,25-dihydroxyvitamin D levels at 25 pg/mL, 30 pg/mL, or higher, e.g. 25-65 pg/mL for an extended period, for example at least one month, at least three months, at least six months, or longer.
  • the formulations described herein can be administered to patients to lower or maintain lowered serum parathyroid hormone levels, preferably an amount that lowers PTH levels by at least 30%, or alternatively the amount needed to reduce serum levels of PTH to the target range for the CKD stage (e.g., for Stage 3 is 35-70 pg/mL (equivalent to 3.85-7.7 pmol/L), for Stage 4 is 70-110 pg/mL (equivalent to 7.7-12.1 pmol/L), and for Stage 5 is 150- 300 pg/mL (equivalent to 16.5-33.0 pmol/L) (defined in K/DOQI Guideline No. 1)).
  • Stage 3 is 35-70 pg/mL (equivalent to 3.85-7.7 pmol/L)
  • for Stage 4 is 70-110 pg/mL (equivalent to 7.7-12.1 pmol/L)
  • for Stage 5 is 150- 300 pg/mL (equivalent to 16.5-33
  • the formulations according to the disclosure herein can be administered to a patient suffering from hyperparathyroidism secondary to chronic kidney disease (e.g., Stage 3 or 4, or Stage 3, 4 or 5) to lower the serum PTH level.
  • hyperparathyroidism secondary to chronic kidney disease e.g., Stage 3 or 4, or Stage 3, 4 or 5
  • the dosages described herein are contemplated for any of the therapeutic methods described herein. It will be appreciated that the actual preferred amount of a vitamin D compound in a specific case will vary according the particular compositions formulated, the mode of application, and the particular situs being treated. Dosages can be determined using conventional considerations, e.g., by customary comparison of the differential activity of the hormone and of a known agent, e.g. by means of an appropriate conventional pharmacological protocol.
  • the specific doses for each particular patient can depend on a wide variety of factors, for example, on the age, body weight, general state of health, sex, on the diet, on the timing and mode of administration, on the rate of excretion, and on medicaments used in combination and the severity of the particular disorder to which the therapy is applied.
  • Patients in need of vitamin D supplementation include healthy subjects and subjects at risk for vitamin D insufficiency or deficiency, for example, subjects with Stage 1, 2, 3, 4 or 5 CKD; infants, children and adults that do not drink vitamin D fortified milk (e.g.
  • lactose intolerant subjects subjects with milk allergy, vegetarians who do not consume milk, and breast fed infants
  • subjects with rickets subjects with dark skin (e.g., in the U.S., 42% of African American women between 15 and 49 years of age were vitamin D deficient compared to 4% of white women); the elderly (who have a reduced ability to synthesize vitamin D and also are more likely to stay indoors); institutionalized adults (who are likely to stay indoors, including subjects with Alzheimer's disease or mentally ill); subjects who cover all exposed skin (such as members of certain religions or cultures); subjects who always use sunscreen (e.g., the application of sunscreen with a Sun Protection Factor (SPF) value of 8 reduces production of vitamin D by 95%, and higher SPF values may further reduce vitamin D); subjects with fat malabsorption syndromes (including but not limited to cystic fibrosis, cholestatic liver disease, other liver disease, gallbladder disease, pancreatic enzyme deficiency, Crohn's disease, inflammatory bowel disease,
  • kidney osteodystrophy including osteomalacia and osteitis fibrosa cystica.
  • compositions and methods of the invention are useful for prophylactic or therapeutic treatment of vitamin D-responsive diseases, i.e., diseases where vitamin D, 25-hydroxyvitamin D or active vitamin D (e.g., 1,25-dihydroxyvitamin D) prevents onset or progression of disease, or reduces signs or symptoms of disease.
  • vitamin D-responsive diseases include cancer (e.g., breast, lung, skin, melanoma, colon, colorectal, rectal, prostate and bone cancer).
  • 1,25-dihydroxyvitamin D has been observed to induce cell differentiation and/or inhibit cell proliferation in vitro for a number of cells.
  • Vitamin D- responsive diseases also include autoimmune diseases, for example, type I diabetes, multiple sclerosis, rheumatoid arthritis, polymyositis, dermatomyositis, scleroderma, fibrosis, Grave's disease, Hashimoto's disease, acute or chronic transplant rejection, acute or chronic graft versus host disease, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis,
  • autoimmune diseases for example, type I diabetes, multiple sclerosis, rheumatoid arthritis, polymyositis, dermatomyositis, scleroderma, fibrosis, Grave's disease, Hashimoto's disease, acute or chronic transplant rejection, acute or chronic graft versus host disease, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis,
  • Vitamin D-responsive diseases also include other inflammatory diseases, for example, asthma, chronic obstructive pulmonary disease, polycystic kidney disease, polycystic ovary syndrome, pancreatitis, nephritis, hepatitis, and/or infection. Vitamin D-responsive diseases have also been reported to include hypertension and cardiovascular diseases.
  • the invention contemplates prophylactic or therapeutic treatment of subjects at risk of or suffering from cardiovascular diseases, for example, subjects with atherosclerosis, arteriosclerosis, coronary artery disease, cerebrovascular disease, peripheral vascular disease, myocardial infarction, myocardial ischemia, cerebral ischemia, stroke, congestive heart failure, cardiomyopathy, obesity or other weight disorders, lipid disorders (e.g. hyperlipidemia, dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia hypoalphalipoproteinemia, hypertriglyceridemia, hypercholesterolemia, and low HDL (high density lipoprotein)), metabolic disorders (e.g.
  • cardiovascular diseases for example, subjects with atherosclerosis, arteriosclerosis, coronary artery disease, cerebrovascular disease, peripheral vascular disease, myocardial infarction, myocardial ischemia, cerebral ischemia, stroke, congestive heart failure, cardiomyopathy, obesity or other weight disorders, lipid disorders (e.g. hyperlipidemia, dyslipidemia including associated diabetic dys
  • Metabolic Syndrome Type II diabetes mellitus, Type I diabetes mellitus, hyperinsulinemia, impaired glucose tolerance, insulin resistance, diabetic complication including neuropathy, nephropathy, retinopathy, diabetic foot ulcer and cataracts), and/or thrombosis.
  • Diseases which can benefit from a modulation in the levels of vitamin D compounds include, but are not limited to: (i) in the parathyroid— hypoparathyroidism, pseudohypoparathyroidism, secondary hyperparathyroidism; (ii) in the pancreas—diabetes; (iii) in the thyroid— medullary carcinoma; (iv) in the skin— psoriasis; wound healing; (v) in the lung— sarcoidosis and tuberculosis; (vi) in the kidney— chronic kidney disease, hypophosphatemic VDR , vitamin D dependent rickets; (vii) in the bone— anticonvulsant treatment, fibrogenisis imperfecta ossium, osteitis fibrosa cystica, osteomalacia, osteoporosis, osteopenia,
  • osteosclerosis renal osteodytrophy, rickets
  • in the intestine glucocorticoid antagonism, idopathic hypercalcemia, malabsorption syndrome, steatorrhea, tropical sprue
  • autoimmune disorders in the intestine— glucocorticoid antagonism, idopathic hypercalcemia, malabsorption syndrome, steatorrhea, tropical sprue; and (ix) autoimmune disorders.
  • the disease that benefits from a modulation in the levels of vitamin D compounds are selected from cancer, dermatological disorders (for example, psoriasis), parathyroid disorders (for example, hyperparathyroidism and secondary
  • hyperparathyroidism hyperparathyroidism
  • bone disorders for example, osteoporosis
  • autoimmune disorders e.g., rheumatosis
  • the formulation can be prepared by procedures well within the capabilities of the ordinary skilled artisan.
  • the components of the matrix e.g. wax and oily vehicle
  • the active e.g., 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3
  • the stabilizer can be added after all matrix components (e.g., waxes and oils) are blended and prior to combination with the active.
  • the mixture can be cooled and stored prior to later division into unit dosage forms, such as filled gelatin capsules.
  • a portion of the oily vehicle, controlled release agent, and emulsifier are heated to a relatively high temperature (e.g., 65 °C) and mixed prior to adding an absorption enhancer, followed by additional mixing until homogenous, then cooling to an intermediate elevated temperature (e.g., 50 °C to 55 °C).
  • an antioxidant preservative and the remainder of the oily vehicle are mixed and heated to an intermediate elevated temperature (e.g., 50 °C), then combined and mixed with the wax mixture until a homogenous solution is obtained.
  • the stabilizer is added, with mixing.
  • a solution of the vitamin D compound(s) in alcohol is combined with the homogenous waxy solution, mixed until a homogenous solution is obtained, preferably filled into capsules, and then cooled to room temperature.
  • a portion of the oily vehicle, controlled release agent, and emulsifier are heated at a temperature of 55 °C to 60 °C and mixed prior to adding an absorption enhancer, followed by additional mixing until homogenous.
  • an antioxidant preservative, the remainder of the oily vehicle, and the stabilizer are mixed and heated to a temperature of 55 °C to 60 °C, then combined and mixed with the wax mixture until a homogenous solution is obtained.
  • a solution of vitamin D compound in alcohol is combined with the homogenous waxy solution, mixed until a homogenous solution is obtained, preferably filled into capsules, and then cooled to room temperature.
  • the formulation preferably is placed in capsules prior to administration to the patient in need of treatment.
  • Such capsules may be hard or soft, and soft capsules are particularly contemplated.
  • the formulation may be filled into gelatin capsules using standard capsule filling machinery, such as by melting the formulation and injection- filling it into soft capsule shells.
  • Example soft capsule shells include VEGICAPS and OPTISHELL technologies (Catalent, Somerset, NJ, USA).
  • the formulation can be made into a unit dosage form by any other suitable processes, for example to yield tablets, sachets, dragees, suppositories, or the like.
  • the formulation is prepared for and administered by oral delivery.
  • the formulation is prepared for and administered as a suppository, e.g. a rectal suppository.
  • the formulation further includes a preservative, such as an antioxidant.
  • a preservative such as an antioxidant.
  • BHT Butylated hydroxytoluene
  • the vitamin D compound is administered in another type of embodiment.
  • the proportions of each of the compounds in the combination being administered will be dependent on the particular disease state being addressed. For example, one may choose to administer 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D3 (e.g., orally) with one or more calcium salts (intended as a calcium supplement or dietary phosphate binder), bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, cholecalciferol, ergocalciferol, active Vitamin D sterols, glycemic and hypertension control agents, various antineoplastic agents and inhibitors of CYP24 and other cytochrome P450 enzymes that can degrade vitamin D agents.
  • calcium salts intended as a calcium supplement or dietary phosphate binder
  • bisphosphonates intended as a calcium supplement or dietary phosphate binder
  • calcimimetics intended as a calcium supplement or dietary phosphate binder
  • calcimimetics intended as a calcium supplement or dietary
  • the formulation is preferably filled into gelatin capsules, but it may also be administered in neat form, or with one or more external coating layers, such as an enteric coating. It is also contemplated that the formulation can be pressed into tablets, and in such cases one or more tablet pressing excipients may be included.
  • a preferred formulation includes 25-hydroxyvitamin D (e.g., about 30 ⁇ g, about 60 ⁇ g, or about 90 ⁇ g 25-hydroxyvitamin D 3 ), about 2 wt% (e.g., 2.32 wt%) anhydrous ethanol, about 10 wt% (e.g., 9.75 wt%) GELUCIRE 44/14, about 20 wt% (e.g., 20.00 wt.%) hard paraffin, about 23 wt% (e.g., 22.55 wt%) GMS, about 35 wt% (e.g., 35.36 wt%) liquid paraffin or mineral oil, about 10 wt% HPMC, and optionally a small amount of preservative (e.g., 0.02 wt% BHT).
  • preservative e.g. 0.02 wt% BHT
  • the Dissolution Medium was 0.05 M pH 6.8 phosphate buffer/1% sodium dodecyl sulfate dissolution medium at 37 ⁇ 0.5 °C, and the apparatus was operated at 100 rotations per minute. Samples were taken at 2, 4, 6, 8, and 12 hours and the 25-hydroxyvitamin D content of each sample was determined using UPLC.
  • Comparative Formulation 1 Aged product according to Comparative Formulation 1 was heat cured and then subject to dissolution testing. Curing consists of applying a heat treatment and has been shown to stabilize pharmaceutical formulations (see, e.g., U.S. Patent No. 6,645,527). Comparative Formulation 1 (aged samples) was heated at 40 °C for 72 hours for curing, and then was stored at room temperature for 8 weeks. Release of 25-hydroxyvitamin D 3 from the cured formulation was tested after storage for 0, 2, 4, and 8 weeks at room temperature. The results are
  • Dissolution Time T 0 2 weeks 4 weeks 8 weeks (hours) % LC % LC % LC
  • Example Formulation B demonstrated a substantially stable dissolution profile following storage for at least 26 weeks at room temperature.
  • Example Formulation C The stability of stabilized formulations comprising 30 ⁇ g (Example Formulation C), 60 ⁇ g (Example Formulation D), or 90 ⁇ g (Example Formulation E) of 25-hydroxyvitamin D 3 was tested using storage conditions of 25 °C and 60% relative humidity and 40 °C and 75% relative humidity.
  • Example Formulations C to E The compositions of Example Formulations C to E are summarized in the table below:
  • VEGICAPS Soft Capsule Shell
  • Example Formulations C to E also exhibited substantially stable dissolution profiles following storage at 40 °C and 75% RH for at least 6 months (Figure 2).
  • the dissolution results are summarized in the table below.
  • the serum concentration of 25-hydroxyvitamin D3 increased gradually following the administration of an oral dose.
  • the increase in 25-hydroxyvitamin D3 was dose proportional and reached an approximate mean maximum observed serum concentration (Cmax) of 32 ng/mL following the administration of the 900 ⁇ g capsule.
  • Cmax concentration of 25-hydroxyvitamin D 3
  • concentrations of 25-hydroxyvitamin D 3 increased rapidly following the administration of the i.v. dose.
  • the bioavailability of the oral doses was approximately 6 to 11%.
  • the terminal half-life (ti /2 ) of 25-hydroxyvitamin D 3 following the administration of the oral dose was approximately 12 to 22 days. No adverse effects on serum calcium or phosphorous, or urine calcium were observed in any treatment group.
  • mean serum total 1,25-dihydroxyvitamin D rose rapidly following the administration of the i.v. injection, increasing from pre-treatment baseline by approximately 13 pg/mL by 6 hours post-dose.
  • mean serum total 1,25-dihydroxyvitamin D increased dose proportionally and gradually by approximately 7 pg/mL by 48 hours post-dose following the administration of the 900 ⁇ g capsule.
  • Serum iPTH showed no meaningful change over the first 96 hours after the i.v. dose was administered. In contrast, serum PTH declined gradually following dosing, reaching a maximum suppression of approximately 20% from pretreatment baseline for subjects who received the 900 ⁇ g capsule.
  • the observed pharmacokinetic parameters for all the treatment groups are summarized in the table below.
  • Cis (isgmL) 18.11 (7.146) 9 19.08 (7,611) 9 35,07 (12,330)
  • a NA NA A NA NA
  • Study B 20 healthy subjects with mean baseline serum 25-hydroxyvitamin D of about 24 ng/mL (range 11 ng/mL to 45 ng/mL) received a single oral dose of a stabilized controlled release capsule comprising 900 ⁇ g of 25-hydroxyvitamin D 3 , 20.00 wt% hard paraffin, 10.00 wt% HPMC, 22.55 wt% GMS, 9.75 wt% GELUCIRE 44/14, 2.32 wt % anhydrous ethanol, 35.36 wt% mineral oil, and 0.02 wt% BHT (Example Formulation F) or a single intravenous dose of 448 ⁇ g 25-hydroxyvitamin D3 in an ethanol solution.
  • a stabilized controlled release capsule comprising 900 ⁇ g of 25-hydroxyvitamin D 3 , 20.00 wt% hard paraffin, 10.00 wt% HPMC, 22.55 wt% GMS, 9.75 wt% GELUCIRE 44/14, 2.32 wt
  • the mean baseline serum 25-hydroxyvitamin D3 concentrations were comparable across treatment groups and ranged from approximately 16 to 20 ng/mL. Following treatment with 25-hydroxyvitamin D3, mean levels of serum 25-hydroxyvitamin D3 increased gradually and in a dose-proportional manner following repeated daily administration of 25-hydroxyvitamin D 3 and began to approach steady-state by 6 weeks (Figure 4).
  • the mean baseline adjusted Cmax values were approximately 28, 60 and 86 ng/mL for the groups administered 30 ⁇ g, 60 ⁇ g and 90 ⁇ g of 25-hydroxyvitamin D3, respectively.
  • the stabilized controlled release formulations of 25-hydroxyvitamin D 3 increased serum total 25-hydroxyvitamin D levels to >30 ng/mL in significantly greater number of subjects in all active groups compared to placebo. Similarly, the stabilized formulations significantly decreased mean plasma iPTH from baseline in all dose groups compared to placebo.
  • the mean serum 25-hydroxyvitamin D level in the 30 ⁇ g dose group at the end of treatment was 37.3 ⁇ 1.8 ng/mL, (slightly higher than K/DOQI-specified minimum adequate level of 30 ng/mL), indicating that 30 ⁇ g was the minimum effective dose.
  • Mean plasma iPTH decreased at end of treatment in proportion to the administered dose of 25-hydroxyvitamin D 3 .
  • the lowest administered dose (30 ⁇ g) decreased iPTH by 20.2 ⁇ 5.8 (SE) %> from pre-treatment baseline, and the highest dose (90 ⁇ g) decreased iPTH by 35.9 ⁇ 4.2%.
  • An increase of 17.2 ⁇ 7.8% was observed at end of treatment in the combined placebo groups.
  • the stabilized formulations of 25-hydroxyvitamin D 3 had no clinically significant effect on corrected albumin-corrected serum calcium, serum phosphorus and urinary calcium excretion. There were no adverse effects on serum calcium or serum phosphorus or urine calcium during the 6-week treatment period.
  • Example 4 Pharmacokinetic and Pharmacodynamic Profile of Modified-Release Calcifediol in CKD Subjects with Secondary Hyperparathyroidism and Vitamin D
  • Eligible subjects in the first cohort were randomized into 3 treatment groups in a 1 : 1 : 1 ratio: 2 groups received the capsules at daily oral doses of 60 or 90 ⁇ g, respectively, and 1 group received a matching placebo capsule.
  • Subjects in cohort 2 were randomized into 2 treatment groups in a 1 : 1 ratio: 1 group received 30 ⁇ g capsules daily and the other received placebo.
  • Subjects in each cohort completed 6 weeks of treatment and entered a 6 week follow-up period, during which PK and PD samples were collected weekly. Serum calcium (Ca), phosphorus (P), 25D 3 , total 1,25-dihydroxyvitamin D (1,25D) and plasma iPTH were monitored weekly during 6 weeks of treatment and 6 weeks of follow-up.
  • ANCOVA models examined the association of 25D 3 exposure with change from baseline for 1,25D and iPTH. Covariates included were baseline eGFR, body weight and height, gender, age, race, diabetic status, and baseline concentration of 1,25D or iPTH.
  • Figure 4 shows the resulting mean baseline-adjusted calcifediol concentrations by treatment group (PK population). Mean levels of serum calcifediol increased gradually and in a dose-proportional manner and began to approach steady-state by 6 weeks. After 6 weeks of follow-up, levels decreased but remained above baseline in all active-treated groups.
  • Figure 5 shows the resulting summary baseline-adjusted PK parameters for calcifediol concentrations by treatment group (PK population).
  • Figure 6 shows the resulting mean baseline-adjusted serum 1 ,25-dihydroxyvitamin D levels during the 6-week treatment (PK population). Mean baseline-adjusted serum total 1,25 dihydroxyvitamin D levels increased over time in those subjects administered the active capsules, compared to those subjects administered placebo.
  • Figure 7 shows a summary of the resulting baseline-adjusted repeat-dose PK parameters for serum 1,25 -dihydroxyvitamin D by treatment group (PK population).
  • Figure 8 shows the resulting mean percent of baseline in plasma iPTH levels during the 6-week treatment (PK population).
  • the active capsules significantly decreased mean plasma iPTH from baseline by 21%, 33% and 39% in all dose groups (30, 60 and 90 ⁇ g, respectively) compared to a 17% increase in the combined placebo group.
  • Figure 9 shows a summary of the resulting baseline-adjusted repeat-dose PK parameters for plasma iPTH by treatment group (PK population).
  • Figures 10 and 11 show the percent change from baseline at EOT for plasma iPTH relative to baseline-adjusted calcifediol and 1,25 -dihydroxyvitamin D exposure (AUCo_6wk) in the PK Population. Percent reductions in plasma iPTH from baseline to EOT increased as serum calcifediol and total 1 ,25 dihydroxyvitamin D exposures during treatment (expressed as baseline- adjusted AUCo_6wk) increased.
  • the stabilized, sustained release 25-hydroxyvitamin D 3 capsules normalized 25D levels in the majority of subjects and significantly reduced iPTH in all dose groups (30, 60 and 90 ⁇ g).
  • the stabilized, sustained release 25-hydroxyvitamin D 3 capsules increased serum 25D 3 and serum 1,25D levels gradually with dose-dependent increases in exposure. Both 25D 3 and total 1,25D exposure were significantly and inversely associated with change from baseline for plasma iPTH. Only eGFR was a significant covariate in both models.
  • compositions are described as including components or materials, it is contemplated that the compositions can also consist essentially of, or consist of, any combination of the recited components or materials, unless described otherwise. Likewise, where methods are described as including particular steps, it is
  • the methods can also consist essentially of, or consist of, any combination of the recited steps, unless described otherwise.
  • the invention illustratively disclosed herein suitably may be practiced in the absence of any element or step which is not specifically disclosed herein.
  • a controlled release formulation of a vitamin D compound comprising one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , the formulation comprising a matrix that releasably binds and controllably releases the vitamin D compound, the matrix comprising a cellulose derivative.
  • a stabilizing agent which is optionally a cellulosic compound, to maintain a difference of less than 30% between the amount of vitamin D compound released at any given time point after four hours during in vitro dissolution after two months exposure to storage conditions of 25 °C and 60% relative humidity and the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions.
  • a stabilized formulation for controlled release of a vitamin D compound comprising a mixture of: one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 ; a wax matrix; and a stabilizing agent, which is optionally a cellulosic compound.
  • a stabilized formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation, said formulation comprising a mixture of: one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 ; a wax matrix; and a stabilizing agent, which is optionally a cellulosic stabilizing agent.
  • a stabilized formulation for controlled release of a vitamin D comprising a mixture of: one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 ; a wax matrix; and an effective amount of a stabilizing agent, optionally a cellulosic compound, to maintain a difference of less than 30% between the amount of vitamin D compound released at any given time point after four hours during in vitro dissolution testing after exposure for two months to storage conditions of 25 °C and 60% relative humidity and the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions.
  • a stabilizing agent optionally a cellulosic compound
  • a stabilized formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation comprising a mixture of: an active-loaded wax matrix comprising one or both of 25-hydroxyvitamin D 2 and 25- hydroxyvitamin D3; and a cellulosic stabilizing agent; wherein the formulation releases an amount of 25-hydroxyvitamin D during in vitro dissolution after two months exposure to storage of 25 °C and 60% relative humidity that varies at any given dissolution time point compared to the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions by 30%> or less in the absence of the cellulosic stabilizing agent.
  • a formulation for controlled release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation comprising an effective amount of a cellulosic compound admixed in the formulation to maintain a change of less than 30% in the amount of 25-hydroxyvitamin D released during in vitro dissolution after exposure to storage conditions of at least one month at 25 °C and 60% relative humidity at any given dissolution time point after four hours compared to the amount released at the same dissolution time point during in vitro dissolution conducted prior to exposing the formulation to the storage conditions.
  • the cellulosic compound or cellulosic stabilizing agent comprises a cellulose ether.
  • the cellulose ether is selected from the group consisting of methylcellulose, hydroxyl propyl methylcellulose, hydroxyl ethyl methylcellulose, hydroxyl ethyl cellulose, and hydroxyl propyl cellulose.
  • the matrix comprises a wax matrix comprising a controlled release agent, an emulsifier, and an absorption enhancer.
  • vitamin D compound comprises 25-hydroxyvitamin D 3 .
  • [00165] 23 The formulation according to paragraph 22, wherein the formulation comprises about 20 wt% paraffin, about 20 wt% to about 25 wt% glycerol monostearate, about 10 wt% a mixture of lauroyl macrogolglycerides and lauroyl polyoxylglycerides, about 30 wt% to about 35 wt% mineral oil, and about 10 wt% to about 15 wt% hydroxyl propyl methylcellulose.
  • a sustained release dosage form in the form of a capsule, tablet, sachet, dragee, or suppository comprising a formulation according to any one of the preceding paragraphs.
  • [00170] 28 The dosage form according to paragraph 27, comprising a capsule.
  • [00171] 29 The dosage form according to paragraph 26, comprising an oral capsule, tablet, sachet, dragee.
  • a stabilized dosage form according to any one of the preceding paragraphs characterized by a dissolution profile providing a release of vitamin D compound of less than 30% at 2 hours; greater than 45% at 6 hours; and greater than 80% at 12 hours.
  • a stabilized sustained release oral dosage form comprising a vitamin D compound characterized by an in vitro dissolution profile providing release of vitamin D compound of less than 30% at 100 to 140 minutes; greater than 45% at 5 to 7 hours; and greater than 80% at 1 1 to 13 hours.
  • [00175] 33 The dosage form of paragraph 32, wherein the release of vitamin D compound is less than 30%> at 2 hours; greater than 45% at 6 hours; and greater than 80% at 12 hours.
  • a stabilized sustained release oral dosage form comprising a vitamin D compound characterized by an in vitro dissolution profile providing release of vitamin D compound of about 20%) to about 40%> at 2 hours; at least 35% at 6 hours; and at least 70% at 12 hours.
  • a stabilized sustained release dosage form comprising a vitamin D compound characterized by a t max following administration of the dosage form to a human patient, of at least 4 hours.
  • a stabilized sustained release dosage form comprising a 25-hydroxyvitamin D compound, the dosage form characterized by providing a baseline-adjusted C max per microgram of 25-hydroxyvitamin D in a range of about 0.0133 ng/niL to about 0.04 ng/mL when
  • a method of administering a stabilized sustained release dosage form comprising a 25-hydroxyvitamin D compound to a human patient comprising administering an effective amount of the dosage form to the patient to provide a baseline-adjusted Cmax of at least about 0.2 ng/mL and less than 110 ng/mL.
  • a method of administering a stabilized sustained release dosage form comprising a 25-hydroxyvitamin D compound to a human patient comprising administering an effective amount of the dosage form to the patient to provide a baseline-adjusted AUCo-inf of at least 52 ng*h/mL and less than 34500 ng*h/mL.
  • a method of vitamin D supplementation comprising administering to a subject in need thereof a formulation or dosage form according to any one of the preceding paragraphs.
  • [00200] 58 A method of treatment or prophylaxis of a vitamin-D responsive disease in a subject comprising administering to the subject a formulation or dosage form according to any one of the preceding paragraphs.
  • the disease is selected from cancer (e.g., breast, lung, skin, melanoma, colon, colorectal, rectal, prostate and bone cancer), autoimmune diseases, for example, type I diabetes, multiple sclerosis, rheumatoid arthritis, polymyositis, dermatomyositis, scleroderma, fibrosis, Grave's disease, Hashimoto's disease, acute or chronic transplant rejection, acute or chronic graft versus host disease, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis, Sjogren's Syndrome, eczema and psoriasis, dermatitis, including atopic dermatitis, contact dermatitis, allergic dermatitis and/or chronic dermatitis, inflammatory diseases, for example, asthma, chronic obstructive pulmonary disease, polycystic kidney disease, polycystic ova
  • hypoalphalipoproteinemia hypertriglyceridemia, hypercholesterolemia, and low HDL (high density lipoprotein)
  • metabolic disorders e.g. Metabolic Syndrome, Type II diabetes mellitus, Type I diabetes mellitus, hyperinsulinemia, impaired glucose tolerance, insulin resistance, diabetic complication including neuropathy, nephropathy, osteoporosis, retinopathy, diabetic foot ulcer and cataracts
  • thrombosis e.g. Metabolic Syndrome, Type II diabetes mellitus, Type I diabetes mellitus, hyperinsulinemia, impaired glucose tolerance, insulin resistance, diabetic complication including neuropathy, nephropathy, osteoporosis, retinopathy, diabetic foot ulcer and cataracts
  • the disease is selected from (i) in the parathyroid— hypoparathyroidism, Pseudohypoparathyroidism, secondary hyperparathyroidism; (ii) in the pancreas—diabetes; (iii) in the thyroid— medullary carcinoma; (iv) in the skin- psoriasis; wound healing; (v) in the lung— sarcoidosis and tuberculosis; (vi) in the kidney- chronic kidney disease, hypophosphatemic VDRR, vitamin D dependent rickets; (vii) in the bone— anticonvulsant treatment, fibrogenisis imperfecta ossium, osteitis fibrosa cystica, osteomalacia, osteoporosis, osteopenia, osteosclerosis, renal osteodytrophy, rickets; (viii) in the intestine— glucocorticoid antagonism, id
  • hyperparathyroidism and secondary hyperparathyroidism include bone disorders (for example osteoporosis) and autoimmune disorders.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
PCT/US2014/028132 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administring same Ceased WO2014143941A1 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
LTEP14717038.5T LT2968172T (lt) 2013-03-15 2014-03-14 Stabilizuota modifikuoto atpalaidavimo vitamino d kompozicija ir jos įvedimo būdas
MYPI2015002281A MY194092A (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administering same
UAA201510090A UA123386C2 (uk) 2013-03-15 2014-03-14 Стабілізований склад вітаміну d із модифікованим вивільненням і спосіб його введення
CA2905409A CA2905409C (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administering same
DK14717038.5T DK2968172T3 (da) 2013-03-15 2014-03-14 Stabiliseret vitamin D formulering med kontrolleret frigivelse og metode til administration
HK16108226.1A HK1220128A1 (zh) 2013-03-15 2014-03-14 稳定化修饰释放维生素d制剂和施用其的方法
SM20200424T SMT202000424T1 (it) 2013-03-15 2014-03-14 Formulazione a base di vitamina d a rilascio modificato stabilizzata e metodo di somministrazione della stessa
EA201591809A EA038867B1 (ru) 2013-03-15 2014-03-14 Стабилизированный состав витамина d с модифицированным высвобождением
PL19217651T PL3650016T3 (pl) 2013-03-15 2014-03-14 Stabilizowana formulacja o zmodyfikowanym uwalnianiu witaminy d i sposób jej podawania
PL14717038T PL2968172T3 (pl) 2013-03-15 2014-03-14 Stabilizowane modyfikowane uwolnienie w formulacji witaminy d oraz taki sam sposób podawania
EP19217651.9A EP3650016B1 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administering same
BR112015023658A BR112015023658A2 (pt) 2013-03-15 2014-03-14 formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
SI201431628T SI2968172T1 (sl) 2013-03-15 2014-03-14 Formulacija vitamina D s stabiliziranim spremenjenim sproščanjem in postopek za dajanje iste
NZ711924A NZ711924B2 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administering same
AU2014228069A AU2014228069B2 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin D formulation and method of administring same
PL18155036T PL3332773T3 (pl) 2013-03-15 2014-03-14 Stabilizowany preparat witaminy D o zmodyfikowanym uwalnianiu i sposób jego podawania
JP2016502712A JP6492051B2 (ja) 2013-03-15 2014-03-14 安定化調整放出ビタミンｄ製剤及びその投与方法
CN202010255439.4A CN111346071B (zh) 2013-03-15 2014-03-14 稳定化修饰释放维生素d制剂和施用其的方法
CN201480024061.XA CN105246464A (zh) 2013-03-15 2014-03-14 稳定化修饰释放维生素d制剂和施用其的方法
ES14717038T ES2809477T3 (es) 2013-03-15 2014-03-14 Formulación de vitamina D de liberación modificada estabilizada y método de administración de la misma
HRP20201284TT HRP20201284T1 (hr) 2013-03-15 2014-03-14 Stabilizirana modificirana formulacija za otpuštanje vitamina d i metoda primjene iste
EP21157479.3A EP3888638A1 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administering same
HK16108396.5A HK1220362B (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administring same
RS20200963A RS60846B1 (sr) 2013-03-15 2014-03-14 Stabilizovana formulacija vitamina d sa modifikovanim oslobađanjem i postupak za davanje iste
MX2015012625A MX2015012625A (es) 2013-03-15 2014-03-14 Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrativa y metodo para administrar la misma.
EP14717038.5A EP2968172B8 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administring same
SG11201507323PA SG11201507323PA (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administring same
EP18155036.9A EP3332773B8 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administering same
CR20190178A CR20190178A (es) 2013-03-15 2014-03-14 Formulación de vitamina d de liberación modificada y estabilizada y método de administración de la misma
IL241456A IL241456B (en) 2013-03-15 2015-09-10 A stabilized formulation with a controlled release of vitamin D, and methods for its administration
SA515361134A SA515361134B1 (ar) 2013-03-15 2015-09-15 صيغة مستقرة ذات إطلاق متحكم فيه لمركب فيتامين د وطريقة إعطائها
PH12015502162A PH12015502162A1 (en) 2013-03-15 2015-09-15 Stabilized modified release vitamin d formulation and method of administering same
AU2019200268A AU2019200268B2 (en) 2013-03-15 2019-01-16 Stabilized modified release vitamin d formulation and method of administering same
IL274841A IL274841A (en) 2013-03-15 2020-05-21 A stabilized formulation with a controlled release of vitamin D, and methods for its administration
CY20201100727T CY1123167T1 (el) 2013-03-15 2020-08-05 Σταθεροποιημενο σκευασμα βιταμινης d τροποποιημενης απελευθερωσης και μεθοδος χορηγησης αυτου
CY20201101109T CY1123568T1 (el) 2013-03-15 2020-11-24 Σκευασμα βιταμινης d σταθεροποιημενης τροποποιημενης απελευθερωσης και μεθοδος χορηγησης αυτου
NO2021007C NO2021007I1 (no) 2013-03-15 2021-02-19 calcifediol
PH12021551127A PH12021551127A1 (en) 2013-03-15 2021-05-17 Stabilized modified release vitamin d formulation and method of administering same
CY20211100683T CY1124393T1 (el) 2013-03-15 2021-07-30 Σταθεροποιημενο σκευασμα βιταμινης d τροποποιημενης απελευθερωσης και μεθοδος χορηγησης αυτου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801896P 2013-03-15 2013-03-15
US61/801,896 2013-03-15

Publications (1)

Publication Number Publication Date
WO2014143941A1 true WO2014143941A1 (en) 2014-09-18

Family

ID=50478969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/028132 Ceased WO2014143941A1 (en) 2013-03-15 2014-03-14 Stabilized modified release vitamin d formulation and method of administring same

Country Status (37)

Country Link
US (7) US9861644B2 (https=)
EP (4) EP3332773B8 (https=)
JP (4) JP6492051B2 (https=)
KR (4) KR101847947B1 (https=)
CN (2) CN105246464A (https=)
AR (1) AR095576A1 (https=)
AU (2) AU2014228069B2 (https=)
BR (1) BR112015023658A2 (https=)
CA (1) CA2905409C (https=)
CL (1) CL2015002659A1 (https=)
CR (1) CR20190178A (https=)
CY (3) CY1123167T1 (https=)
DE (1) DE202014011525U1 (https=)
DK (3) DK3650016T3 (https=)
EA (2) EA201991774A1 (https=)
EC (1) ECSP23024864A (https=)
ES (3) ES2834900T3 (https=)
HK (1) HK1220128A1 (https=)
HR (3) HRP20201284T1 (https=)
HU (3) HUE051923T2 (https=)
IL (2) IL241456B (https=)
LT (3) LT2968172T (https=)
MX (2) MX2015012625A (https=)
MY (2) MY200794A (https=)
NO (1) NO2021007I1 (https=)
PE (1) PE20151761A1 (https=)
PH (2) PH12015502162A1 (https=)
PL (3) PL3332773T3 (https=)
PT (3) PT3650016T (https=)
RS (3) RS62176B1 (https=)
SA (1) SA515361134B1 (https=)
SG (2) SG11201507323PA (https=)
SI (3) SI3650016T1 (https=)
SM (3) SMT202000651T1 (https=)
TW (1) TWI659753B (https=)
UA (1) UA123386C2 (https=)
WO (1) WO2014143941A1 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017178932A (ja) * 2016-03-23 2017-10-05 株式会社ファンケル ビタミンｄ３安定化組成物
WO2017182237A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
CN108135868A (zh) * 2015-09-25 2018-06-08 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d及其制品的辅助疗法
US10300078B2 (en) 2013-03-15 2019-05-28 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
EP3204047B1 (en) 2015-02-06 2020-05-27 Faes Farma, S.A. Calcifediol soft capsules
US10668089B2 (en) 2006-06-21 2020-06-02 Opko Ireland Global Holdings, Ltd. Method of treating and preventing secondary hyperparathyroidism
US11007204B2 (en) 2006-02-03 2021-05-18 Opko Renal, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US11154509B2 (en) 2007-04-25 2021-10-26 Eirgen Pharma Ltd. Methods for controlled release oral dosage of a vitamin D compound
US11590148B2 (en) * 2018-04-03 2023-02-28 Eirgen Pharma Ltd. Use of calcifediol in bariatric surgery patients
JP2023071723A (ja) * 2014-08-07 2023-05-23 オプコ アイルランド グローバル ホールディングス リミテッド ２５－ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
RU2837000C2 (ru) * 2018-04-03 2025-03-25 Опко Айэлэнд Глобал Холдингз, Лтд. Применение кальцифедиола у пациентов, перенесших бариатрическую операцию
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
CN108902985A (zh) * 2018-06-08 2018-11-30 唐飞 25-羟基维生素d3在制备保健食品中的应用
WO2020044314A1 (en) 2018-08-31 2020-03-05 Opko Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using
KR102715550B1 (ko) * 2018-12-10 2024-10-10 신성대학교 산학협력단 유효성분을 함유하는 왁스 파티클 및 이의 제조방법
CN109632444A (zh) * 2018-12-24 2019-04-16 郑州安图生物工程股份有限公司 液态25-羟基维生素d校准品稀释液
EP3920938A1 (en) * 2019-02-06 2021-12-15 EirGen Pharma Ltd. Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
CN110917169A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 帕立骨化醇胶囊剂及其制备方法
WO2021151905A1 (en) 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US20210308151A1 (en) 2020-04-06 2021-10-07 Eirgen Pharma Ltd. Activating endogenous antimicrobials to treat sars-cov-2 infection
EP4157231A1 (en) 2020-05-31 2023-04-05 EirGen Pharma Ltd. Hard capsule dosage form and uses thereof
CN111991404B (zh) * 2020-10-10 2021-08-13 西南医科大学 防治真菌感染的复合维生素d及其应用
IT202100015845A1 (it) 2021-06-17 2022-12-17 I B N Savio S R L Processo di formulazione della vitamina d / vitamin d formulation process
CN115266992A (zh) * 2022-08-02 2022-11-01 人福普克药业（武汉）有限公司 一种测定维生素d类软胶囊溶出的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000074A1 (en) * 1994-06-24 1996-01-04 Ben-Gurion University Of The Negev Pharmaceutical compositions comprising vitamin-d analogs
US6645527B2 (en) 1997-07-02 2003-11-11 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
WO2004098617A2 (en) * 2003-05-07 2004-11-18 Osteologix A/S Controlled release composition containing a strontium salt
WO2012145491A2 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
US10998308B2 (en) 2019-07-22 2021-05-04 Texas Instruments Incorporated Area-efficient bi-directional ESD structure

Family Cites Families (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008517A2 (en) 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS55139320A (en) 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
US4442093A (en) 1981-05-15 1984-04-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
JPS57188520A (en) 1981-05-15 1982-11-19 Kureha Chem Ind Co Ltd Antihyperkalemia
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
JPS58206524A (ja) 1982-05-26 1983-12-01 Kureha Chem Ind Co Ltd 抗腫瘍剤
US4448721A (en) 1982-09-20 1984-05-15 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 compounds and process for preparing same
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4795327A (en) 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
DE3676235D1 (de) 1985-06-04 1991-01-31 Teijin Ltd Arzneizubereitung mit verzoegerter wirkstoffabgabe.
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US4795642A (en) 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US5167965A (en) 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4892821A (en) 1987-07-08 1990-01-09 Taisho Pharmaceutical Co., Ltd. Method for preparing vitamin D compounds
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JP2525478B2 (ja) 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンｄ製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
TW212761B (https=) 1991-04-09 1993-09-11 Takeda Pharm Industry Co Ltd
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DK0600079T3 (da) 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
US5354743A (en) 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
EP0769936A1 (en) 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
JP3372259B2 (ja) 1995-09-21 2003-01-27 ウィスコンシン・アルムニ・リサーチ・ファウンデーション カルシトリオール誘導体およびそれらの用途
DE19536387A1 (de) 1995-09-29 1997-04-03 Basf Ag Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
US5939408A (en) 1996-05-23 1999-08-17 Hoffman-La Roche Inc. Vitamin D3 analogs
NO971934L (no) 1996-05-23 1997-11-24 Hoffmann La Roche Flourinerte vitamin D3 -analoger
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンｄ化合物を配合した眼内投与剤
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
US5872113A (en) 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
US6096876A (en) 1997-08-06 2000-08-01 Shriners Hospitals For Children 1-α-hydroxylase materials and methods
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US5919986A (en) 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
JPH11158074A (ja) 1997-12-03 1999-06-15 Hayashi Tomie 高アミノ酸付加活性型ビタミンｄ強化組成物
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
JP2002507415A (ja) 1998-03-25 2002-03-12 キュタノジェン， インコーポレイテッド 癌の予防および処置のための方法
WO1999049870A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US8133694B2 (en) 1998-06-25 2012-03-13 Immundiagnostik Ag Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
ATE291418T1 (de) 1998-07-28 2005-04-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6214376B1 (en) 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
SK287111B6 (sk) 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
DE69940821D1 (de) 1998-10-09 2009-06-10 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE344039T1 (de) 1999-04-01 2006-11-15 Univ Johns Hopkins Nicht-calcemische, transkriptionell-aktive, schwefelhaltige analoga von 1-alpha, 25- dihydroxyvitamin d3 mit antiproliferativer wirkung
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU5139600A (en) 1999-05-27 2000-12-18 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
AU6866900A (en) 1999-08-31 2001-03-26 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
EP1301479A2 (en) 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
AU8013801A (en) 2000-08-29 2002-03-13 Nisshin Kasei Co Ltd Hard capsule
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
JP2002302447A (ja) 2001-04-03 2002-10-18 Shimizu Pharmaceutical Co Ltd 局所投与用癌治療剤
RU2262922C2 (ru) 2001-05-15 2005-10-27 Уорнер-Ламберт Компани Ллс Способ прессования для получения лекарственной формы фенитоина натрия
CA2452577C (en) 2001-07-05 2011-04-19 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
IL159853A0 (en) 2001-07-17 2004-06-20 Teva Pharma Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US6870833B2 (en) 2001-07-20 2005-03-22 Net2Phone, Inc. Active voice messaging
US7166585B2 (en) 2001-08-22 2007-01-23 Cytochroma Inc. 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP4436674B2 (ja) 2001-10-12 2010-03-24 ジョンズ ホプキンス ユニバーシティ １α，２５−ジヒドロキシビタミンＤ３の低カルシウム血症性オキシム類似体
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
KR20100047349A (ko) 2001-11-22 2010-05-07 모리시타 진탄 가부시키가이샤 비젤라틴계 캡슐 피막 조성물 및 이를 이용한 캡슐
GB0128415D0 (en) 2001-11-27 2002-01-16 Univ Sheffield Medicaments
BR0214679A (pt) 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
AU2003226148A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20030190355A1 (en) 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
JP2005528383A (ja) 2002-04-10 2005-09-22 ミラー，フレッド，エイチ． 多重相・複数コンパートメントカプセルシステム
CA2484244A1 (en) 2002-05-02 2003-11-13 Cytochroma Inc. Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof
ATE543796T1 (de) 2002-06-13 2012-02-15 Univ Johns Hopkins 24-sulfoximine vitamin d3 derivate
DE60334378D1 (de) 2002-07-05 2010-11-11 Temrel Ltd Zusammensetzung zur kontrollierten wirkstoffabgabe
MY142179A (en) 2002-07-25 2010-10-15 Glaxo Group Ltd Multicomponent pharmaceutical dosage form
KR100699516B1 (ko) 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2002368245A1 (en) 2002-09-26 2004-04-19 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004058235A2 (en) 2002-12-16 2004-07-15 Teva Pharmaceutical Industries Ltd. Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
CA2510228C (en) 2002-12-18 2012-10-30 Johns Hopkins University 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3
EP1592410B1 (en) 2003-02-11 2008-07-23 Alza Corporation Methods and dosage forms with modified layer geometry
EP1628643B9 (en) 2003-04-14 2013-06-12 Fmc Corporation Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
WO2004098507A2 (en) 2003-04-30 2004-11-18 Bioxell S.P.A. 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
CA2529495C (en) 2003-06-16 2013-02-05 Solx, Inc. Shunt for the treatment of glaucoma
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
AU2003903382A0 (en) 2003-07-03 2003-07-17 Medvet Science Pty Ltd Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof
US20070155664A1 (en) 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
EP1694333A2 (en) 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
AU2004308712A1 (en) 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a HIV protease inhibitor
BRPI0508612A (pt) 2004-03-10 2007-08-14 Schering Aktiengellschaft composições compreendendo drospirenona dispersa molecularmente
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
WO2006007323A2 (en) 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
KR20070043806A (ko) 2004-07-29 2007-04-25 사노피-아벤티스 ｐＨ에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제
KR101398747B1 (ko) 2004-08-19 2014-05-26 디에스엠 아이피 어셋츠 비.브이. 지용성 물질의 신규한 조성물
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
AU2004325362B2 (en) 2004-12-03 2012-09-06 Council Of Scientific And Industrial Research Process of preparation of biodegradable films from semi refined kappa carrageenan
IL166114A0 (en) 2005-01-03 2006-01-15 Calcident Active Ltd Long-acting controlled-release pharmaceutical preparation for use in the oral cavity
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
DE102005011029A1 (de) 2005-03-08 2006-09-14 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die perorale Applikation mit gesteuerter Freisetzung von Wirkstoffen
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
US7895596B2 (en) 2005-09-13 2011-02-22 Hewlett-Packard Development Company, L.P. Processor assignment in multi-processor systems
JP2009509992A (ja) 2005-09-29 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー ２５−ヒドロキシビタミンｄに対する抗体
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
WO2007047327A2 (en) 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
US8293270B2 (en) 2005-10-26 2012-10-23 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
KR101372110B1 (ko) 2005-11-01 2014-03-14 씨피 켈코 유에스, 인코포레이티드 고점도 디우탄 검 및 제조 방법
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
MXPA05014091A (es) 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus
WO2007092221A2 (en) 2006-01-31 2007-08-16 Health Research Inc. Method for identifying altered vitamin d metabolism
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
GB0606426D0 (en) 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
EP2024436A1 (en) 2006-06-06 2009-02-18 Fmc Corporation Kappa-2 carrageenan composition and products made therefrom
US20080109983A1 (en) 2006-11-10 2008-05-15 Kegel, Llc Zero Turning Radius Lane Maintenance Machine
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
US7387328B2 (en) 2006-09-07 2008-06-17 Willey Barry A Cycle windshield
EP1912400A1 (en) 2006-10-10 2008-04-16 Matsushita Electric Industrial Co., Ltd. Method and apparatus for mobile IP route optimization
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
EP2124963A4 (en) 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc COMPOSITION WITH A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D
WO2008097646A1 (en) 2007-02-09 2008-08-14 Schering Corporation Methods to treat and/or prevent mucositis
US8491937B2 (en) 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
EP2135345A4 (en) 2007-03-20 2016-12-14 Electrolock Inc ROEBEL WINDING WITH CONDUCTIVE FELT
US20100144679A1 (en) 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
PL2148661T3 (pl) * 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
PT3335712T (pt) 2007-04-25 2025-10-23 Opko Renal Llc Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
US8592401B2 (en) 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
US20090004284A1 (en) 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CN201113125Y (zh) * 2007-07-10 2008-09-10 富士康(昆山)电脑接插件有限公司 电池连接器
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
EP2042165A1 (de) 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
US20090104206A1 (en) 2007-10-19 2009-04-23 Mark Zamoyski Bone microenvironment modulated migraine treatments
CA2610819A1 (en) 2007-12-12 2008-12-02 Multi Formulations Ltd. Particles in a capsule
ES2599761T5 (en) 2008-02-13 2025-06-18 Dsm Ip Assets Bv Use of 25-hydroxy-vitamin d3 and vitamin d to affect human muscle physiology
CN101951917A (zh) 2008-02-13 2011-01-19 帝斯曼知识产权资产管理有限公司 用25-羟基维生素d3治疗高血压
ES2588241T3 (es) 2008-02-13 2016-10-31 Dsm Ip Assets B.V. Tratamiento de la hiperglucemia con 25-hidroxivitamina D3 y vitamina D
CN106214683A (zh) 2008-02-13 2016-12-14 帝斯曼知识产权资产管理有限公司 维生素d和25‑羟基维生素d3的组合
US20110039809A1 (en) 2008-02-13 2011-02-17 Neil Robert Buck Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporisis
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
JP2011518169A (ja) 2008-04-15 2011-06-23 オステオジェネックス インコーポレイティド 骨増殖を変化させるための化合物及び方法
US8324191B2 (en) 2008-07-11 2012-12-04 Biolink Life Sciences, Inc Combined calcium, magnesium and vitamin D supplements
WO2010011906A1 (en) 2008-07-24 2010-01-28 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
MX2011003047A (es) 2008-09-24 2011-04-14 Evonik Roehm Gmbh Composicion farmaceutica de opioide de liberacion controlada ph dependiente con resistencia contra la influencia de etanol.
ES2425762T3 (es) 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
WO2010084038A1 (en) * 2009-01-23 2010-07-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Controlled release pharmaceutical or food formulation and process for its preparation
CH700543A2 (de) 2009-03-03 2010-09-15 Innogel Ag Film auf Basis von Stärke.
KR101760534B1 (ko) 2009-09-10 2017-07-21 에프엠씨 코포레이션 이음매 없는 알기네이트 캡슐
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
CA2775246C (en) 2009-10-20 2020-03-24 Herbonis Ag Composition comprising solanum glaucophyllum for preventing and/or treating hypocalcaemia and for stabilizing blood calcium levels
IT1396937B1 (it) 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR20120005228A (ko) 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법
BR112013002721B8 (pt) 2010-08-04 2021-05-25 Scherer Technologies Llc R P composição formadora de filme para cápsulas moles, cápsulas moles e seu invólucro
US20130263297A1 (en) 2010-11-10 2013-10-03 Cedars-Sinai Medical Center Methods of treating cancer
US20120135103A1 (en) 2010-11-30 2012-05-31 Mead Johnson Nutrition Company Staged Infant Feeding Regimen To Promote Healthy Development And Growth
CN106924268A (zh) 2010-12-06 2017-07-07 帝斯曼知识产权资产管理有限公司 用25‑羟基‑维生素d3治疗与嗜酸性粒细胞趋化因子增高有关的病症
EP2635611B1 (en) 2010-12-28 2017-01-11 Future Diagnostics B.V. Release reagent for vitamin d
WO2012117236A1 (en) 2011-03-02 2012-09-07 D3 Pharma Limited Vitamin d composition
ES2617654T3 (es) 2011-04-20 2017-06-19 Suheung Co., Ltd. Composición de la cubierta de cápsula blanda de origen no animal que tiene dureza de la cubierta y desintegración, mejoradas
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实（上海）商贸有限公司 可食用液体填充的多糖胶囊
ES2660362T3 (es) 2011-05-27 2018-03-22 Dsm Ip Assets B.V. Procedimiento de extrusión y producto resultante del mismo.
US20130085121A1 (en) 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
US9877929B2 (en) * 2011-10-13 2018-01-30 Premier Dental Products Company Topical vitamin D and ubiquinol oral supplement compositions
WO2014029953A1 (en) 2012-08-21 2014-02-27 Cipla Limited Hot melt extruded (hme) pharmaceutical composition of cinacalcet
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PT106978A (pt) 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
TWI645864B (zh) * 2014-03-14 2019-01-01 歐科二代智財控股公司 經穩定之修飾釋放維他命ｄ調配物及其服用方法
EA201790332A1 (ru) 2014-08-07 2017-06-30 Опко Айэлэнд Глобал Холдингз Лтд. Дополнительная терапия 25-гидроксивитамином d
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000074A1 (en) * 1994-06-24 1996-01-04 Ben-Gurion University Of The Negev Pharmaceutical compositions comprising vitamin-d analogs
US6645527B2 (en) 1997-07-02 2003-11-11 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
WO2004098617A2 (en) * 2003-05-07 2004-11-18 Osteologix A/S Controlled release composition containing a strontium salt
WO2012145491A2 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
US10998308B2 (en) 2019-07-22 2021-05-04 Texas Instruments Incorporated Area-efficient bi-directional ESD structure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"USP 29-NF 24, Dissolution <711> physical tests and determinations", 2006, UNITED STATES PHARMACOPEIAL CONVENTION, INC., article "United States Pharmacopeia", pages: 2673 - 2682
"USP 29-NF 24, Dissolution <711> physical tests and determinations", 2006, UNITED STATES PHARMACOPEIAL CONVENTION, INC., pages: 2673 - 2682
RAPURI P B ET AL: "Effect of vitamins D2 and D3 supplement use on serum 25OHD concentration in elderly women in summer and winter", CALCIFIED TISSUE INTERNATIONAL, NEW YORK, NY, US, vol. 74, no. 2, 1 February 2004 (2004-02-01), pages 150 - 156, XP002454820, ISSN: 0171-967X, DOI: 10.1007/S00223-003-0083-8 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911398B2 (en) 2006-02-03 2024-02-27 Opko Renal, Llc Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US11007204B2 (en) 2006-02-03 2021-05-18 Opko Renal, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US10668089B2 (en) 2006-06-21 2020-06-02 Opko Ireland Global Holdings, Ltd. Method of treating and preventing secondary hyperparathyroidism
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
US11154509B2 (en) 2007-04-25 2021-10-26 Eirgen Pharma Ltd. Methods for controlled release oral dosage of a vitamin D compound
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US11253528B2 (en) 2013-03-15 2022-02-22 Eirgen Pharma Ltd. Stabilized modified release Vitamin D formulation and method of administering same
US10350224B2 (en) 2013-03-15 2019-07-16 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
US10357502B2 (en) 2013-03-15 2019-07-23 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
US12478631B2 (en) 2013-03-15 2025-11-25 Eirgen Pharma Ltd. Stabilized modified release vitamin D formulation and method of administering same
US10300078B2 (en) 2013-03-15 2019-05-28 Opko Ireland Global Holdings, Ltd. Stabilized modified release vitamin D formulation and method of administering same
US10493084B2 (en) 2014-08-07 2019-12-03 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US11007205B2 (en) 2014-08-07 2021-05-18 Eirgen Pharma Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US11738033B2 (en) 2014-08-07 2023-08-29 Eirgen Pharma Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP2023071723A (ja) * 2014-08-07 2023-05-23 オプコ アイルランド グローバル ホールディングス リミテッド ２５－ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
EP3204047B1 (en) 2015-02-06 2020-05-27 Faes Farma, S.A. Calcifediol soft capsules
EP3689380A1 (en) 2015-02-06 2020-08-05 Faes Farma, S.A. Calcifediol soft capsules
JP7432069B2 (ja) 2015-09-25 2024-02-16 エアジェン ファーマ リミテッド ２５－ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
JP2018534254A (ja) * 2015-09-25 2018-11-22 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
CN108135868A (zh) * 2015-09-25 2018-06-08 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d及其制品的辅助疗法
JP2021120370A (ja) * 2015-09-25 2021-08-19 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
JP2017178932A (ja) * 2016-03-23 2017-10-05 株式会社ファンケル ビタミンｄ３安定化組成物
JP7034595B2 (ja) 2016-03-23 2022-03-14 株式会社ファンケル ビタミンｄ３安定化組成物
US12208106B2 (en) 2016-03-28 2025-01-28 Eirgen Pharma Ltd. Methods of vitamin D treatment
IL261850A (en) * 2016-03-28 2018-10-31 Opko Ireland Global Holdings Ltd Methods of treatment with vitamin d
AU2017253821B2 (en) * 2016-03-28 2022-11-03 Opko Ireland Global Holdings, Limited Methods of vitamin D treatment
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
WO2017182237A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
AU2023200536B2 (en) * 2016-03-28 2025-01-16 Opko Ireland Global Holdings, Limited Methods of vitamin D treatment
US11173168B2 (en) 2016-03-28 2021-11-16 Eirgen Pharma Ltd. Methods of treating vitamin D insufficiency in chronic kidney disease
EP4596045A3 (en) * 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
US11590148B2 (en) * 2018-04-03 2023-02-28 Eirgen Pharma Ltd. Use of calcifediol in bariatric surgery patients
RU2837000C2 (ru) * 2018-04-03 2025-03-25 Опко Айэлэнд Глобал Холдингз, Лтд. Применение кальцифедиола у пациентов, перенесших бариатрическую операцию
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Also Published As

Publication number Publication date
NZ711924A (en) 2021-01-29
EA201591809A1 (ru) 2016-02-29
JP2021155460A (ja) 2021-10-07
HK1256895A1 (en) 2019-10-04
US12478631B2 (en) 2025-11-25
ECSP23024864A (es) 2023-05-31
CY1123568T1 (el) 2022-03-24
SG10201703517VA (en) 2017-06-29
CR20190178A (es) 2019-09-02
PT2968172T (pt) 2020-08-27
ES2809477T3 (es) 2021-03-04
JP2018012737A (ja) 2018-01-25
NO2021007I1 (no) 2021-02-19
JP6492051B2 (ja) 2019-03-27
SI3650016T1 (sl) 2022-04-29
SA515361134B1 (ar) 2017-10-16
US20190374555A1 (en) 2019-12-12
SI3332773T1 (sl) 2021-03-31
RS61132B1 (sr) 2020-12-31
MY200794A (en) 2024-01-16
DK3332773T3 (da) 2020-11-30
EP3332773B8 (en) 2020-10-14
EP3888638A1 (en) 2021-10-06
ES2834900T3 (es) 2021-06-21
DK3650016T3 (da) 2021-08-09
MX2015012625A (es) 2016-07-06
KR102203003B1 (ko) 2021-01-13
HRP20211265T1 (hr) 2021-11-12
AR095576A1 (es) 2015-10-28
CL2015002659A1 (es) 2016-04-15
SMT202100439T1 (it) 2021-11-12
HUE055591T2 (hu) 2021-12-28
PT3650016T (pt) 2021-07-28
CN111346071B (zh) 2025-12-19
US9861644B2 (en) 2018-01-09
KR101847947B1 (ko) 2018-05-28
US20140349979A1 (en) 2014-11-27
EP3650016B1 (en) 2021-05-05
US20180117068A1 (en) 2018-05-03
CA2905409A1 (en) 2014-09-18
JP2016517429A (ja) 2016-06-16
KR20210078463A (ko) 2021-06-28
HUE052014T2 (hu) 2021-04-28
SMT202000424T1 (it) 2020-09-10
SMT202000651T1 (it) 2021-01-05
CN111346071A (zh) 2020-06-30
LT2968172T (lt) 2020-10-26
AU2019200268B2 (en) 2021-04-01
EP3650016A1 (en) 2020-05-13
JP2019135264A (ja) 2019-08-15
IL241456B (en) 2020-06-30
IL274841A (en) 2020-07-30
SG11201507323PA (en) 2015-10-29
LT3650016T (lt) 2021-09-27
US10357502B2 (en) 2019-07-23
EA038867B1 (ru) 2021-10-29
CY1124393T1 (el) 2022-07-22
ES2882567T3 (es) 2021-12-02
TW201707689A (zh) 2017-03-01
UA123386C2 (uk) 2021-03-31
HUE051923T2 (hu) 2021-03-29
PT3332773T (pt) 2020-11-24
HK1220128A1 (zh) 2017-04-28
EP2968172A1 (en) 2016-01-20
AU2019200268A1 (en) 2019-02-07
JP6533268B2 (ja) 2019-06-19
RS62176B1 (sr) 2021-08-31
EA201991774A1 (ru) 2019-11-29
MX2020011736A (es) 2021-01-08
US20180271885A1 (en) 2018-09-27
HRP20201284T1 (hr) 2020-12-11
HRP20201869T1 (hr) 2021-04-02
CY1123167T1 (el) 2021-10-29
HK1220362A1 (zh) 2017-05-05
KR20140140004A (ko) 2014-12-08
KR20190095216A (ko) 2019-08-14
US11253528B2 (en) 2022-02-22
PH12015502162A1 (en) 2016-01-25
PL3332773T3 (pl) 2021-03-08
TWI659753B (zh) 2019-05-21
US20260034148A1 (en) 2026-02-05
CN105246464A (zh) 2016-01-13
JP7282832B2 (ja) 2023-05-29
CA2905409C (en) 2023-01-03
BR112015023658A2 (pt) 2017-07-18
RS60846B1 (sr) 2020-10-30
SI2968172T1 (sl) 2020-12-31
AU2014228069B2 (en) 2019-01-31
DE202014011525U1 (de) 2021-11-11
US20220125806A1 (en) 2022-04-28
PL3650016T3 (pl) 2021-12-27
PH12021551127A1 (en) 2021-12-13
PE20151761A1 (es) 2015-12-16
EP2968172B8 (en) 2020-10-07
EP3332773B1 (en) 2020-08-26
IL241456A0 (en) 2015-11-30
US20180271884A1 (en) 2018-09-27
LT3332773T (lt) 2020-12-10
MY194092A (en) 2022-11-11
KR20140113374A (ko) 2014-09-24
EP3332773A1 (en) 2018-06-13
DK2968172T3 (da) 2020-09-14
EP2968172B1 (en) 2020-07-22
PL2968172T3 (pl) 2020-12-28
AU2014228069A1 (en) 2015-10-01
US10300078B2 (en) 2019-05-28
US10350224B2 (en) 2019-07-16

Similar Documents

Publication Publication Date Title
US12478631B2 (en) Stabilized modified release vitamin D formulation and method of administering same
HK40020409A (en) Stabilized modified release vitamin d formulation and method of administering same
HK40020409B (en) Stabilized modified release vitamin d formulation and method of administering same
HK1256895B (en) Stabilized modified release vitamin d formulation and method of administering same
HK40033528A (en) Stabilized modified release vitamin d formulation and method of administering same
HK1220362B (en) Stabilized modified release vitamin d formulation and method of administring same
NZ711924B2 (en) Stabilized modified release vitamin d formulation and method of administering same
TW201934117A (zh) 經穩定之修飾釋放維他命d調配物及其服用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14717038

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2905409

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 241456

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/012625

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2014717038

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016502712

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: NC2019/0003040

Country of ref document: CO

Ref document number: P1255/2015

Country of ref document: AE

Ref document number: 15218413

Country of ref document: CO

Ref document number: 002016-2015

Country of ref document: PE

Ref document number: 12015502162

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2014228069

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201506434

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 201591809

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: CR2015-000570

Country of ref document: CR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015023658

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015023658

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150915

WWR Wipo information: refused in national office

Ref document number: 515361134

Country of ref document: SA

WWW Wipo information: withdrawn in national office

Ref document number: 274841

Country of ref document: IL